FOXO4-DRI (10 mg Vial) Dosage Protocol

FOXO4-DRI (10 mg Vial) Dosage Protocol

FOXO4-DRI (10 mg Vial) peptide vial

Quickstart Highlights

FOXO4-DRI (also known as Proxofim) is a synthetic D-retro-inverso peptide designed to selectively induce apoptosis in senescent cells by disrupting the FOXO4–p53 protein interaction[1][2]. When this interaction is blocked, p53 translocates to the mitochondria in senescent cells, triggering their programmed death while sparing healthy cells[1]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for precise insulin-syringe measurements.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
  • Typical daily range: 250–500 mcg once daily (gradual titration over 16 weeks).
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles[8].

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–4 250 mcg 7.5 units (0.075 mL)
Weeks 5–8 375 mcg 11 units (0.11 mL)
Weeks 9–12 500 mcg 15 units (0.15 mL)
Weeks 13–16 500 mcg 15 units (0.15 mL)

Frequency: Inject once daily subcutaneously[7]. This schedule uses the standard 3.0 mL dilution to maintain injection volumes under 0.2 mL for all doses. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake)[8].
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

  • Peptide Vials (FOXO4-DRI, 10 mg each):

    • 8 weeks ≈ 3 vials
    • 12 weeks ≈ 4 vials
    • 16 weeks ≈ 5 vials
  • Insulin Syringes (U-100):

    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

    • 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
    • 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
    • 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100-count boxes

FOXO4-DRI (10 mg Vial) peptide vial View Supplier
Insulin Syringes for subcutaneous peptide injection View Supplier
Bacteriostatic water 10ml for peptide reconstitution View Supplier
EasyTouch alcohol prep pads for injection site sterilization View Supplier

Protocol Overview

Concise summary of the once-daily regimen.

  • Goal: Selectively clear senescent cells via disruption of FOXO4–p53 binding[1][2].
  • Schedule: Daily subcutaneous injections for 8–16 weeks with gradual dose escalation.
  • Dose Range: 250–500 mcg daily; starting low and titrating upward over time.
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw[8].

Dosing Protocol

Suggested daily titration approach.

  • Start: 250 mcg daily for the first 4 weeks; increase gradually as tolerated.
  • Mid-Phase: 375 mcg daily during Weeks 5–8.
  • Target: 500 mcg daily by Weeks 9–16.
  • Frequency: Once per day (subcutaneous)[7].
  • Cycle Length: 8–16 weeks; longer cycles may use intermittent dosing schedules as tolerated[4].
  • Timing: Any consistent time; rotate injection sites to minimize local irritation.

Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; minimize moisture exposure[8].
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 1 month when using bacteriostatic water[8].
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • If long-term storage of reconstituted solution is needed, aliquot into single-use vials and freeze to minimize degradation[8].

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes (typically 29–31 gauge, 0.5 inch needle) for each injection[9]; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) at least 1 inch apart to reduce local irritation[10].
  • Clean the injection site with an alcohol swab and allow to dry before injecting[9].
  • Inject slowly and steadily; no need to aspirate for subcutaneous injections[11].
  • Document daily dose and site rotation to maintain consistency throughout the protocol.

How This Works

FOXO4-DRI is a synthetic peptide that selectively targets senescent cells by blocking the FOXO4–p53 protein interaction[1][2]. In normal cells, FOXO4 binds to p53 and sequesters it in the nucleus. In senescent cells, disrupting this interaction causes p53 to translocate to the mitochondria, triggering apoptotic cell death specifically in aged, dysfunctional cells while sparing healthy ones[1]. Animal studies have demonstrated that FOXO4-DRI can reduce senescent cell burden, improve tissue function, and mitigate age-related pathologies[3][4][5]. The peptide’s D-retro-inverso configuration enhances its stability and resistance to proteolytic degradation[2].

Potential Benefits & Side Effects

Observations from preclinical literature.

  • Promotes selective clearance of senescent cells in various tissues, including aged organs and pathological conditions[3][4][5].
  • Animal studies show improvements in tissue regeneration, reduced inflammation, and enhanced organ function following senescent cell clearance[3][5].
  • In aged mice, FOXO4-DRI treatment improved testosterone levels and markers of cellular health[3].
  • No human clinical safety or efficacy data currently exist[6]; tolerability in humans remains uncharacterized.
  • Injection-site reactions (mild redness, irritation) may occur with subcutaneous administration[10].

Lifestyle Factors

Complementary strategies for optimal outcomes.

  • Maintain a balanced, nutrient-dense diet rich in antioxidants and anti-inflammatory compounds.
  • Combine regular resistance training and cardiovascular activity to support cellular health and metabolic function.
  • Prioritize sleep quality and stress management, both of which influence cellular senescence pathways.
  • Stay well-hydrated and avoid excessive alcohol consumption or smoking, which can accelerate cellular aging.

Injection Technique

General subcutaneous guidance from clinical best-practice resources[9][10][11].

  • Clean the vial stopper and skin with alcohol; allow to dry[9].
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (use 90° for adequate fat layer, 45° if thin)[11][12].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[11].
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and local irritation[10].
  • Release the pinch and withdraw the needle; apply gentle pressure with gauze if slight bleeding occurs.

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References


  • Nature Communications Biology
    — FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
    View Source

  • Nature Cell
    — Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging (original FOXO4-DRI discovery)
    View Source

  • Aging (Albany NY)
    — FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
    View Source

  • Journal of Cellular and Molecular Medicine
    — FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice
    View Source

  • Cell
    — Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice (senolytic mechanism context)
    View Source

  • Aging (Albany NY) — Methods & Protocols
    — FOXO4-DRI safety note: no human clinical dosing data exist yet
    View Source

  • PubMed
    — A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides
    View Source

  • Bachem
    — Care and Handling of Peptides (storage, reconstitution, stability guidance)
    View Source

  • MedlinePlus
    — Subcutaneous (SQ) injections: technique, site selection, and safety
    View Source

  • American Diabetes Association
    — Insulin injection site rotation and lipohypertrophy prevention
    View Source

  • CDC
    — Vaccine administration: subcutaneous route (angle, site; no aspiration)
    View Source

  • CDC (Subcutaneous Injection PDF)
    — Technique diagram and site guidance for subcutaneous injections
    View Source

  • NCBI Bookshelf
    — Best practices for injection (asepsis, preparation, and administration)
    View Source

  • PMC
    — Subcutaneous Drug Injection Review: pharmacologic considerations of the subcutaneous route
    View Source

  • Pure Lab Peptides
    — FOXO4-DRI (10 mg) product page (quality and batch documentation)
    View Source